The biopharma intelligence edge
SatyaBio surfaces the strategic signals your competitors haven't seen. Our knowledge graph connects biology, clinical evidence, and deal dynamics to deliver conviction-grade insights in hours.
Second-order signals, surfaced first
The highest-value decisions depend on patterns that span biology, clinical evidence, competitive dynamics, and deal history. SatyaBio maps these connections across millions of data points to reveal undervalued assets, mechanism-of-action gaps, and strategic white space before the market prices them in.
From question to conviction in hours
When a board question lands or a deal window opens, weeks of traditional analysis isn't viable. SatyaBio delivers executive-grade analysis with the speed the question demands and keeps it current as data evolves. Living intelligence, not static deliverables.
Intelligence shaped to your thesis
Generic frameworks waste time. SatyaBio starts from your therapeutic priorities, your competitive set, and your investment thesis. The output maps directly to how your team evaluates opportunities — no translation layer required.
Latest from SatyaBio Intelligence
Original biopharma analysis from the SatyaBio team. Competitive landscapes, clinical readouts, deal flow, and the strategic signals the market is underpricing.
Browse our AnalysesKRAS Inhibitor Landscape Post-AACR: BridgeBio Restructures to Accelerate Beyond G12C
Mapping next-gen KRAS programs after BridgeBio's oncology spinoff leadership change
Roche Oral MS Candidate: Efficacy Signal vs. Hepatotoxicity Risk
Analyzing the clinical trade-off and competitive implications for multiple sclerosis
Lilly's $3.25B Kelonia Acquisition: The In Vivo CAR-T Thesis Takes Shape
Why Eli Lilly paid $3.25B upfront for in vivo CAR-T and what it signals for cell therapy
Oral GLP-1 Wars: Wegovy Pill vs. Lilly's Foundayo Prescription Trajectories
Tracking early Rx data as Novo and Lilly battle for the oral obesity market
AstraZeneca Eyes 5th Ultomiris Indication After IgA Nephropathy Trial Win
C5 inhibitor franchise expansion and implications for complement-targeted therapies
Merck-Google AI Partnership: What a $1B Enterprise Deal Means for Drug Discovery
Evaluating the strategic logic behind Merck's AI infrastructure bet with Google
Where fragmented data becomes connected knowledge
SatyaBio is built on a proprietary knowledge graph that continuously acquires, structures, and links information from across the biopharma ecosystem. Connected knowledge, not another data dump without context.
A billion relationships, already mapped
Our proprietary knowledge graph captures billions of relationships across drugs, targets, mechanisms, clinical outcomes, deals, and competitive moves — structured and linked so you can query what matters.
Comprehensive coverage, continuously updated
Hundreds of sources refreshed daily — clinical trials, regulatory filings, patent data, deal terms, conference presentations, and more. Coverage that compounds, not snapshots that expire.
Every insight traces to source
No black-box conclusions. Every claim, every data point, every pattern SatyaBio surfaces links back to the underlying source documents so your team can verify and build on what they find.
Your data stays yours
Your queries, your analyses, your proprietary data — it all stays private. We never use client data to train models or share insights across accounts. Built for the sensitivity pharma demands.
The platform
Export Anywhere
Every analysis exports to PowerPoint, Excel, or PDF. Structured data ready for your board deck, IC memo, or LP report.
See what your team has been missing
Book a demo to see how SatyaBio can transform your biopharma intelligence workflow.
Open Platform